

2022 Material Information (6469 Great Tree)

Date of announcement	Subject	Statement
2022/01/26	Clarification of Media Reports	<p>1.Date of occurrence of the event:2022/01/25</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Name of the reporting media:Money DJ</p> <p>6.Content of the report: The media reported that Great Tree made a great leap forward in profit last year...The institutional investor estimates that the Company's after-tax per share will exceed NTD 6.5 last year, hitting a new high.The trend of earnings dividend policy has also attracted much attention.</p> <p>7.Cause of occurrence:To clarify media coverage on MOPS website.</p> <p>8.Countermeasures: The Company didn't provide financial forecast. The reported numbers are all self-estimated by institute investor based on the company's released monthly revenue and self-reported pre-tax profits. The actual financial results shall be referred to the Company's official announcements.</p> <p>9.Any other matters that need to be specified:None</p>
2022/02/23	Clarification of Media Reports	<p>1.Date of occurrence of the event:2022/02/23</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Name of the reporting media:Anue</p> <p>6.Content of the report: Anue news headlines 「 The Asian institutional investor first published their evaluation of Great Tree Pharmacy Co.,</p>

Date of announcement	Subject	Statement
		<p>Ltd,optimistic about the three major advantages, and the stock price target price is 330 』</p> <p>「 The Asian institutional investor beleve that Great Tree Pharmacy plans to open up to 1,000 sotres by 2025 from 248 today, and grow its market from 3% to 12% 』</p> <p>「 The Asian institutional investor also forecast net profit to grow by 25-32% from 2022 to 2024 』</p> <p>7.Cause of occurrence:To clarify media coverage on MOPS website.</p> <p>8.Countermeasures: The Company didn't provide financial forecast. The reported numbers are all self-estimated by institute investor based on the company's released monthly revenue and self-reported pre-tax profits. The actual financial results shall be referred to the Company's official announcements.</p> <p>9.Any other matters that need to be specified:None</p>
2022/02/24	Clarification of Media Reports	<p>1.Date of occurrence of the event:2022/02/24</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Name of the reporting media:Commercial Times</p> <p>6.Content of the report: Commercial Times news headlines 「 Great Tree Pharmacy and POYA are praised by the instituional investor and consider their warrants worth noting. 』</p> <p>「 According to the research department of HSBC Securities Taiwan,..., the net profit from 2022 to 2024 will increase by 32%, 29%,and 25% respectively;HSBC's inital evaluation gave a "buy" invetstment rating, and it is speculated that the reasonable sotck price in the next 12 months will be TWD 300. 』</p> <p>「 According to the instituional investor estimates, the scale of Great Tree Pharmacy continues to expand.It is estimated that the annual growth rate from 2021 to 2023 will exceed 20%. During the same period, EPS will be 5.57, 7.34 and 9.44 respectively. 』</p>

Date of announcement	Subject	Statement
		<p>7.Cause of occurrence:To clarify media coverage on MOPS website.</p> <p>8.Countermeasures: The Company didn't provide financial forecast. The reported numbers are all self-estimated by institute investor based on the company's released monthly revenue and self-reported pre-tax profits. The actual financial results shall be referred to the Company's official announcements.</p> <p>9.Any other matters that need to be specified:None</p>
2022/02/25	Great Tree Pharmacy Co., Ltd.'s Board of Directors approved the convening of the 2022 Annual Shareholders' Meeting	<p>1.Date of the board of directors resolution:2022/02/25</p> <p>2.General shareholders' meeting date:2022/05/31</p> <p>3.General shareholders' meeting location:Great Tree Pharmacy Co., Ltd. (17F,No.186 ,Fuxing Rd.,Taoyuan Dist.,Taoyuan City)</p> <p>4.Cause for convening the meeting I.Reported matters: (1).To report the business report of 2021 (2).To report the Audit Committee's review report of 2021 (3).To report the compensation to employees and remuneration to directors of 2021 (4).To accept the proposal for distribution of 2021 earnings(cash dividend).</p> <p>5.Cause for convening the meeting II.Acknowledged matters: (1).To accept 2021 Business Report and Financial Statements (2).To accept the proposal for distribution of 2021 earnings</p> <p>6.Cause for convening the meeting III.Matters for Discussion: (1).Proposal for a new share issue through capitalization for earnings (2).Amendments to the Company's Regulations Governing the Acquisition and Disposal of Assets</p> <p>7.Cause for convening the meeting IV.Election matters:None.</p> <p>8.Cause for convening the meeting V.Other Proposals:None.</p> <p>9.Cause for convening the meeting VI.Extemporaneous Motions:not applicable.</p>

Date of announcement	Subject	Statement
		<p>10.Book closure starting date:2022/04/02</p> <p>11.Book closure ending date:2022/05/31</p> <p>12.Whether to announce proposal for profit distribution or loss off-setting in “Status of dividend distribution” section of MOPS:Yes</p> <p>13.Please explain the reason for not announcing proposal for profit distribution or loss off-setting:not applicable</p> <p>14.Any other matters that need to be specified: According to article 172-1 of Company Act, the company accepts proposals from shareholder in the period between 2022/03/25 and 2022/04/06 ,and in the place of Great tree Pharmacy Co., Ltd.'s head office.(18F,No.186, Fuxing Rd., Taoyuan Dist., Taoyuan City)</p>
2022/02/25	Resolution to issue new shares for capital increase through profits by Board of Directors	<p>1.Date of the board of directors resolution:2022/02/25</p> <p>2.Source of capital increase funds:2021 profits</p> <p>3.Whether to adopt shelf registration (Yes, please state issuance period/No):No</p> <p>4.Total monetary value of the issuance and number of shares issued (shares issued not including those distributed to employees if consisting in capital increase from earnings or capital surplus):18,224,142 shares/182,241,420 NTD</p> <p>5.If adopting shelf registration, monetary value and number of shares to be issued this time:NA</p> <p>6.The remaining monetary value and shares after this issuance when adopting shelf registration:NA</p> <p>7.Par value per share:10 NTD</p> <p>8.Issue price:NA</p> <p>9.Number of shares subscribed for by or allocated to employees:NA</p> <p>10.Number of shares publicly sold:NA</p> <p>11.Ratio of shares subscribed by or allotted as stock dividends to existing shareholders: The shareholders will be entitled to receive 257 shares for each 1,000 shares.</p> <p>12.Handling method for fractional shares and shares unsubscribed for by the deadline: The existing shareholders may apply by themselves to combine fractional share of less than one share into one</p>

Date of announcement	Subject	Statement
		<p>share within five days after the basis date of dividend distribution. If abandoned to combine or cannot be combined into one share, such fractional shares will be purchased by persons arranged by the Chairman as authorized by the BOD.</p> <p>13.Rights and obligations of these newly issued shares: same as existing shares</p> <p>14.Utilization of the funds from the capital increase: to increase the operational capital</p> <p>15.Any other matters that need to be specified:</p> <p>(1)If there is any outstanding shares changed due to the change of the Company's capital stock, the Shareholders' meeting empowers the Board of Directors to handle.</p> <p>(2)Upon the approval of the Annual Shareholders' Meeting and the competent authorities, it is proposed that the Board of Directors be authorized to resolve the ex-rights date to distribute.</p>
2022/02/25	Great Tree Pharmacy Co., Ltd. Board of Directors approved dividend distribution	<p>1.Date of the board of directors resolution:2022/02/25</p> <p>2.Year or quarter which dividends belong to :year 2021</p> <p>3.Period which dividends belong to:2021/01/01~2021/12/31</p> <p>4.Appropriations of earnings in cash dividends to shareholders (NT\$ per share):NT\$2.57</p> <p>5.Cash dividends distributed from legal reserve and capital reserve to shareholders (NT\$ per share):Nil</p> <p>6.Total amount of cash dividends to shareholders (NT\$):NT\$182,241,423</p> <p>7.Appropriations of earnings in stock dividends to shareholders (NT\$ per share):NT\$2.57</p> <p>8.Stock dividends distributed from legal reserve and capital reserve to shareholders (NT\$ per share):Nil</p> <p>9.Total amount of stock dividends to shareholders (shares):18,224,142</p> <p>10.Any other matters that need to be specified:None.</p> <p>11.Per value of common stock:NT\$10</p>
2022/02/25	Announcement on the 2021 Consolidated financial report made by Board of Directors	<p>1.Date of the board of directors submitted or approved:2022/02/25</p> <p>2.Date of the audit committee approved:2022/02/25</p> <p>3.Start and end dates of financial reports or unaudited financial information of the reporting</p>

Date of announcement	Subject	Statement
		<p>period(XXXX/XX/XX~XXXX/XX/XX): 2021/01/01~2021/12/31</p> <p>4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):11,280,942</p> <p>5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):2,943,003</p> <p>6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):492,312</p> <p>7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):509,670</p> <p>8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):407,761</p> <p>9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):407,418</p> <p>10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):5.83</p> <p>11.Total assets end of the period (thousand NTD):7,389,864</p> <p>12.Total liabilities end of the period (thousand NTD):5,437,368</p> <p>13.Equity attributable to owners of parent end of the period (thousand NTD):1,931,870</p> <p>14.Any other matters that need to be specified:NA</p>
2022/02/25	The Board of Directors approved the 2021 distributable compensation for employees and directors.	<p>1.Date of occurrence of the event:2022/02/25</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):head office</p> <p>4.Reciprocal shareholding ratios:not applicable</p> <p>5.Cause of occurrence:In accordance with the order No.1050001900 issued by FSC on 2016/01/30</p> <p>6.Countermeasures:not applicable</p> <p>7.Any other matters that need to be specified:as follows</p> <p>(1)The sum of directors' compensation:4,555,841 NTD</p> <p>(2)The sum of employees' compensation:15,356,767 NTD</p> <p>(3)The employees' and directors' compensation was distributed by cash.</p> <p>(4)The above numbers are the same as the recognized expense of 2021.</p>

Date of announcement	Subject	Statement
2022/02/25	Great Tree Pharmacy Co., Ltd.'s Board of Directors resolved to issue 2022 1st employee stock warrants	<p>1.Date of the board of directors resolution:2022/02/25</p> <p>2.Issue period: Within one year since the date of receipt for notice of the competent authority's approval and effectiveness;issued at once or in tranches depending on actual requirements. The actual issue date is determined by the chairman authorized by the board of directors.</p> <p>3.Eligibility criteria for optionees: Restricted to the full-time employees with specific positions or special contributions of the company or its domestic and foreign subsidiaries that are with over 50%(inclusive) shareholding held by the Company directly or indirectly. The Chairman shall determine the employees who are entitled to the options and the no. of options to be granted after taking into consideration factors including but not limited to responsibilities, work performance and overall contribution or development potential and other factors, and then submit the decision to the Board of Directors for approval. For employees who are directors or managerial officers, approval by the Remuneration Committee must be obtained first,which shall then be submitted to the Boards of Directors for approval. The cumulative no. of shares a single employee can subscribe for by exercising the options granted to him/her by the Company under Paragraph 1, Article 56-1 of the Regulations Governing the Offering and Issuance of Securities by Securities Issuers (the"Regulations Governing Offering and Issuance"),in combination with the cumulative no. of restricted stock awards obtained by such employee,shall not exceed 0.3% of the total issued shares. The above,in combination with the cumulative no. of shares such employee can subscribe for by exercising the stock warrants granted under Paragraph 1,Article 56 shall not exceed 1% of the total issued shares.</p> <p>4.Number of total issued units of the employee stock warrants:4,000 units</p> <p>5.Number of shares each stock warrant unit may subscribe for:1,000 shares</p> <p>6.Total number of new shares to be issued due to exercise of options, or the no.of shares for buyback as required by Article 28-2 of the Securities and Exchange Act:</p>

Date of announcement	Subject	Statement								
		<p>The total number of new shares to be issued for the exercise of these options shall be 4,000,000 shares.</p> <p>7.Subscription price: The subscription price shall consist in the closing price for the Company's common stock on the day these employee stock warrants are issued.</p> <p>8.Period of subscription rights: (1)Optionees may exercise their options, respectively,after 2 years have elapsed since the granting of the stock warrants. The duration of these stock warrants shall be 5 years. The stock warrants may not be transferred, pledged ,assigned as a gift, or otherwise disposed by the optionee, except by inheritance. Once duration has elapsed,rights for options that have not been exercised shall be deemed as waived, and optionees may no longer claim right to exercise their subscription rights.</p> <table border="0" data-bbox="712 724 1675 951"> <tr> <td style="padding-right: 40px;">Grant period</td> <td>Ceiling for proportion of stock warrants exercisable (accumulated)</td> </tr> <tr> <td>After 2 years</td> <td>40%</td> </tr> <tr> <td>After 3 years</td> <td>70%</td> </tr> <tr> <td>After 4 years</td> <td>100%</td> </tr> </table> <p>(2)The Company shall have the right to forfeit and cancel stock warrants for which rights have not been vested or exercised yet in the event that the optionee violates his/her employment contract, service agreement, work rules or laws after the stock warrants have been granted by the Company.</p> <p>9.Types of shares which may be subscribed for:Common shares of the Company.</p> <p>10.Handling method for employee resignation/inheritance: (1)Resignation(including voluntary resignation, disability resignation, leave without pay, severance and expulsion) The vested stock warrants may be exercised to the exercisable extent within the one month from the date of resignation. In the event that it falls within the non-exercisable period stipulated in these regulations, the exercisable period shall be deferred retroactively by the same duration as the respective duration period. All rights for unvested</p>	Grant period	Ceiling for proportion of stock warrants exercisable (accumulated)	After 2 years	40%	After 3 years	70%	After 4 years	100%
Grant period	Ceiling for proportion of stock warrants exercisable (accumulated)									
After 2 years	40%									
After 3 years	70%									
After 4 years	100%									

Date of announcement	Subject	Statement
		<p>stock warrants shall be deemed as waived upon the date of resignation.</p> <p>(2)Retirement For the granted stock warrants, the employee can exercise all the rights to execute the shares upon retirement unless the sotck warrants is limited to be exercised after two years. Thus, it is not subject to the limit of the proportion of stock options that can be exercised at the end of the relevant time period in Article 5, Paragraph 2 of the Plan. However,the right to subscribe for shares shall be exercisable within one year from the date of retirement or when two years have passed since the stock option were granted(mainly based on the later date), but may not exceed the duration of the stock warrants.</p> <p>(3)Death The vested sotck warrants may be exercised by the heir withn one year from the date of death or before the expiration of the warrants (whichever is earilier).Unvested stock warrants shall lose validity from the date of death.</p> <p>(4)Non-reinstatement or Death from Occupational Hazards: 1.For the options already vested to an employee who cannot continue to work because of disability as a result of occupational hazard,such options may be exercisable on the date on which it is confirmed that the Optionee cannot be reinstated.Except for the restriction that the subscription right may be exercised after the 2nd anniversary of the options vested to the employees, the options not yet vested are not subject to the subscription percentage restriciton in Article 5,Paragraph 2 of the Plan. Such options may be exercisable within one year after the date on which it is confirmed that the Optionee cannot be reinstated or after the 2nd anniversary of the issurance date of the option, whichever is later, up to the end of the Term.</p> 2.For the options already vested to an employee died as a result of occupational hazards,such options may be exercisable on the date on which the heir acquires the right of inheritance.Except for the restriction that the subscription right may ve exercised after the 2nd anniversary of the options not yet vested are not subject to the subscription percentage restriction in Article 5,Paragraph 2 of the Plan. Such options may be exercisable within one year after the date of death or after the 2nd anniversary of the issurance date of the option, whichever is later, up to

Date of announcement	Subject	Statement
		<p>the end of the Term.</p> <p>(5)Leave of Absence without pay: For the options already vested to those employees taking leave of absence without pay due to requirement of the laws and regulations, suffering from a dread disease, great change of family, study abroad, etc. approved by the Company, such options may be exercisable within 1 month after the date of leave of absence. For the options not yet vested, calculation of the length of service shall be deferred for the period of leave of absence without pay, and such options may be exercisable after the reinstatement up to the end of the Term.</p> <p>(6)Transfer: Any employee(optionee) of the Company has been transferred to an affiliate in which the Company holds less than 50% voting rights, such optionee's rights and obligations related to the options shall be handled by analogy to the procedure for the job-leaving. However, if the optionee is transferred based on the Company's request, he/she may, after obtaining approval from the Chairman or the authorized officer, exercise his right to subscribe to the shares according to the following vesting schedule and subscription percentage set forth in Article 5, Paragraph 2 herein.</p> <p>(7)Options not exercised by the Optionee or his/her heir within the aforesaid period shall become null and void.</p> <p>11.Other criteria for subscription: The handling method for stock warrants on which rights have been waived is that the Company shall cancel any stock warrants on which rights have been waived, and these shall not be issued again.</p> <p>12.Method for performance of contract: New common shares issued by the Company shall be delivered.</p> <p>13.Adjustment of subscription price: In case of any change in the amount of the common shares of the Company, unless the Company issues securities or warrants convertible into common shares or issues new shares for employees' bonus, the exercise price shall be adjusted.</p> <p>14.Procedures for exercising options:</p>

Date of announcement	Subject	Statement
		<p>The Optionee shall fill out an exercise request form and submit such to the Company or the Company's securities agent.</p> <p>15.Rights and obligations after exercising options: The rights and obligations of the subscribed common shares are the same as the Company's original common shares.</p> <p>16.Reference date for any additional share exchange, stock swap, or subscription:NA</p> <p>17.Possible dilution of equity in case of any additional share exchange, stock swap, or subscription:NA</p> <p>18.Other important terms and conditions:None.</p> <p>19.Any other matters that need to be specified:None.</p>
2022/03/07	Clarification of Media Reports	<p>1.Date of occurrence of the event:2022/03/07</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Name of the reporting media:investor</p> <p>6.Content of the report: Investor news headlines 「 It is estimated that the revenue of Great Tree Pharmacy will decrease in February, but the benefits of the old stores are significant. It is estimated that the revenue growth this year will exceed 20% 」 「 Great Tree Pharmacy(6469)aims to increase the number of stores this year by 20%. Although it mainly focuses on small community stores, with the expansion effect of the increase in the proportion of stores, the annual revenue growth still has the opportunity to challenge more than 20%. 」</p> <p>7.Cause of occurrence:To clarify media coverage on MOPS website.</p> <p>8.Countermeasures: The Company didn't provide financial forecast. The reported numbers are all self-estimated by institute investor based on the company's released monthly revenue and self-reported pre-tax profits.The actual financial results shall be referred to the Company's official announcements.</p>

Date of announcement	Subject	Statement
		9.Any other matters that need to be specified:None
2022/04/06	Great Tree Pharmacy Co., Ltd.'s Board of Directors approved the convening of the 2022 Annual Shareholders' Meeting(Add)	<p>1.Date of the board of directors resolution:2022/04/06</p> <p>2.General shareholders' meeting date:2022/05/31</p> <p>3.General shareholders' meeting location:Great Tree Pharmacy Co., Ltd.(17F,No.186,Fuxing Rd., Taoyuan Dist., Taoyuan City)</p> <p>4.Shareholders meeting will be held by means of (physical shareholders meeting/ visual communication assisted shareholders meeting /visual communication shareholders meeting):physical shareholders meeting</p> <p>5.Cause for convening the meeting I.Reported matters:</p> <p>(1).To report the business report of 2021</p> <p>(2).To report the Audit Committee's review report of 2021</p> <p>(3).To report the compensation to employees and remuneration to directors of 2021</p> <p>(4).To accept the proposal for distribution of 2021 earnings(cash dividend).</p> <p>6.Cause for convening the meeting II.Acknowledged matters:</p> <p>(1).To accept 2021 Business Report and Financial Statements</p> <p>(2).To accept the proposal for distribution of 2021 earnings</p> <p>7.Cause for convening the meeting III.Matters for Discussion:</p> <p>(1).Proposal for a new share issue thorough capitalization for earnings</p> <p>(2).Amendments to the Company's Regulations Governing the Acquisition and Disposal of Assets</p> <p>(3).Discussion of private placement of common shares and/or private placement of domestic convertible corporate bonds.(NEW)</p> <p>8.Cause for convening the meeting IV.Election matters:None.</p> <p>9.Cause for convening the meeting V.Other Proposals:None.</p> <p>10.Cause for convening the meeting VI.Extemporaneous Motions:not applicable</p> <p>11.Book closure starting date:2022/04/02</p>

Date of announcement	Subject	Statement
		<p>12.Book closure ending date:2022/05/31</p> <p>13.Any other matters that need to be specified: According to article 172-1 of Company Act, the company accepts proposals from shareholder in the period between 2022/03/25 and 2022/04/06 ,and in the place of Great Tree Pharmacy Co., Ltd's head office.(18F, No.186, Fuxing Rd., Taoyuan Dist., Taoyuan City)</p>
2022/04/06	Great Tree Pharmacy Co., Ltd.'s Board of Directors resolved to conduct private placement of domestic convertible corporate bonds	<p>1.Date of the board of directors resolution:2022/04/06</p> <p>2.Name of the corporate bonds:Domestic convertible corporate bonds in private placement</p> <p>3.Total amount issued: It will be proposed for the shareholders meeting to authorize the Board of Directors to choose appropriate timing and fund fundraising instrument(s) by one or a combination of methods:conduct private placement of common shares and/or conduct private placement of domestic convertible corporate bonds, within the limit of 2 million common shares, depending on the market conditions and the Company's needs, in accordance with the applicable laws and regulations and the following fund raising method principles. When domestic convertible corporate bonds are issued through private placement, the number of common shares that can be converted from privately placed convertible corporate bonds shall be within the aforementioned scope of 2 million shares, and shall be calculated in accordance with the conversion price determined at the time of private placement.</p> <p>4.Face value per bond: par value of NT\$100,000</p> <p>5.Issue price: The issue price shall be no less than 80% of the theoretical price.</p> <p>6.Issuance period: The Board of Directors is authorized to determine this.</p> <p>7.Coupon rate: The Board of Directors is authorized to determine this.</p> <p>8.Types, names, monetary values and stipulations of collaterals: N/A</p> <p>9.Use of the funds raised by the offering and utilization plan: The funds raised hereby shall serve to either increase working capital, strengthen the financial structure and support the company to expand its marketing channels increase its market share.</p>

Date of announcement	Subject	Statement
		<p>10.Trustees of the corporate bonds:N/A</p> <p>11.Guarantor(s) for the issuance:N/A</p> <p>12.Agent for payment of the principal and interest: N/A</p> <p>13.Where convertible into shares, the price and the rules for conversion: The Board of Directors is authorized to determine this.</p> <p>14.Sell-back conditions: The Board of Directors is authorized to determine this.</p> <p>15.Buyback conditions: The Board of Directors is authorized to determine this.</p> <p>16.Reference date for any additional share exchange, stock swap, or subscription: N/A</p> <p>17.Possible dilution of equity in case of any additional share exchange, stock swap, or subscription: N/a</p> <p>18.For additional share exchange or subscription, possible influence of change in shareholding ratio of TPEX-listed common shares if all privately placed corporate bonds are converted and shares subscribed for (no.of TPEX -listed common shares (a), (a) / outstanding common shares): N/A</p> <p>19.Please explain any countermeasures for lower circulation in shareholding if the aforesaid estimated no.of TPEX-listed common shares does not reach 5 million and the ratio does not reach 25%: N/A</p> <p>20.Any other matters that need to be specified:</p> <p>(1)Except for the transfer restriction regulated by Article 43-8, Securities and Exchange Act, the rights and obligations of the new privately placed common shares converted from domestic convertible bonds are the same as the issued common shares. Privately placed securities in principle may not be transferred and may be filed with the Competent Authority for retroactive handling of public issuance procedures and listing where three full years have elapsed since the delivery date.</p> <p>(2)It will be submitted to a shareholders meeting that the Chairman is authorized with full power to adjust, determine, and conduct the important part of the plan for privately placed domestic convertible bonds, such as terms and conditions of issuance, particulars of the plan, funds to be raised, the purpose of the funds, implementation schedule, and expected returns, and so on, due to the instruction or requirement from the</p>

Date of announcement	Subject	Statement
		Competent Authority or to the necessary amendment or adjustment in response to objective factors. Besides the aforementioned authorization, the Chairman intends to obtain the authorization by a shareholders meeting to sign and negotiate the contracts and documents related to this private placement plan on behalf of the Company and to handle all matters for this private placement plan.
2022/04/06	Great Tree Pharmacy Co., Ltd.'s Board of Directors resolved to conduct private placement of common shares	<p>1.Date of the board of directors resolution:2022/04/06</p> <p>2.Types of securities privately placed:Common shares</p> <p>3.Counterparties for private placement and their relationship with the Company:</p> <p>(1)The counterparties for this private placement shall meet the qualifications for specific persons listed in Article 43-6 of the Securities and Exchange Act, and are limited to strategic investors, prioritizing those who could benefit the Company's long-term development, competitiveness, and rights of existing shareholders.</p> <p>(2)In order to enhance competitiveness, increase operating efficiency and long-term development, strategic investors can directly or indirectly improve the Company's the finance, business, brand, market share, purchase, management and development.</p> <p>(3)The Company has not found specific persons yet and is proposed to authorize the Board of Directors to find specific persons and handle related matters.</p> <p>4.Number of shares or bonds privately placed:</p> <p>It will be proposed for the shareholders meeting to authorize the Board of Directors to choose appropriate timing and fund fundraising instrument(s) by one or a combination of methods:conduct private placement of common shares and/or conduct private placement of domestic convertible corporate bonds, within the limit of 2 million common shares, depending on the market conditions and the Company's needs, in accordance with the applicable laws and regulations and the following fund raising method principles.When domestic convertible corporate bonds are issued through private placement, the number of common shares that can be converted from privately placed convertible corporate bonds shall be within the aforementioned scope of 2 million shares, and shall be calculated in accordance with the conversion price determined at the time of private placement.</p>

Date of announcement	Subject	Statement
		<p>5.Amount limit of the private placement: To be determined</p> <p>6.Pricing basis of private placement and its reasonableness:</p> <p>(1)The issue price of the privately placed common shares shall not be lower than 80 percent of the reference price. The reference price shall be the higher of the following two calculations:</p> <p style="padding-left: 40px;">A.The simple average closing price of the common shares for either the 1, 3, or 5 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends or capital reduction.</p> <p style="padding-left: 40px;">B.The simple average closing price of the common shares for the 30 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends, or capital reduction.</p> <p>(2)The setting of the privately placed domestic unsecured convertible corporate bonds price is not lower than 80 percent of the reference price, the setting method of which is compliance with the existing laws and regulation; hence, it is of reasonability.The reference price for calculation and the actual conversion price shall be the higher of the following two calculations:</p> <p style="padding-left: 40px;">A.The simple average closing price of the common shares for either the 1,3, or 5 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends or capital reduction.</p> <p style="padding-left: 40px;">B.The simple average closing price of the common shares for the 30 business days before the price determination date, after adjustment for any distribution of stock dividends, cash dividends, or capital reduction.</p> <p>(3)The subscription price for common shares of this private placement shall be determined with reference to the price of the Company's common shares, in accordance with the Directions for Public Companies Conducting Private Placements of Securities. Thus, the price should be reasonable.</p> <p>7.Use of the funds raised in the private placement:</p> <p style="padding-left: 40px;">The funds raised hereby shall serve to either increase working capital, strengthen the financial structure and support the company to expand its marketing channels increase its market share.</p> <p>8.Reasons for conducting non-public offering:</p> <p style="padding-left: 40px;">Based on the status of the capital market, timeliness and feasibility of fundraising, issuance cost, and the actual</p>

Date of announcement	Subject	Statement
		<p>needs to attract strategic investors. Privately placed securities cannot be freely traded within three years, can ensure the long-term cooperation between the Company and strategic investors, and authorizing the Board of Directors to conduct private placement according to the Company's actual business needs effectively increases flexibility and freedom for fundraising.</p> <p>9.Objections or qualified opinions from independent Board of Directors: None</p> <p>10.Actual price determination date: N/A</p> <p>11.Reference price: N/A</p> <p>12.Actual private placement price, and conversion or subscription price: N/A</p> <p>13.Rights and obligations of these new shares privately placed: The rights and obligations of the privately placed common shares are the same with the issued common shares. Except for the transfer restriction on objects regulated by Article 43-8, Securities and Exchange Act, privately placed securities in principle may not be transferred until three full years after the delivery date. The Board of Directors is intended to be authorized by a special shareholders meeting and may be filed with the Competent Authority for retroactive handling of public issuance procedures and listing where three full years have elapsed since the delivery date.</p> <p>14.Reference date for any additional share exchange, stock swap, or subscription: N/A</p> <p>15.Possible dilution of equity in case of any additional share exchange, stock swap, or subscription: N/A</p> <p>16.For additional share exchange or subscription, possible influence of change in shareholding ratio of TPEX –listed common shares if all privately placed corporate bonds are converted and shares subscribed for (no.of TPEX –listed common shares (a), (a) / outstanding common shares): N/A</p> <p>17.Please explain any countermeasures for lower circulation in shareholding if the aforesaid estimated no.of TPEX – listed common shares does not reach 5 million and the ratio does not reach 25%: N/A</p> <p>18.Any other matters that need to be specified: None.</p>
2022/05/12	Announcement on the	1.Date of the board of directors submitted or approved:2022/05/12

Date of announcement	Subject	Statement
	2022Q1 Consolidated financial report made by Board of Directors	2.Date of the audit committee approved:2022/05/12 3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX): 2022/01/01~2022/03/31 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):3,193,826 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):841,288 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):139,226 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):149,205 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):118,055 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):117,964 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):1.67 11.Total assets end of the period (thousand NTD):7,602,723 12.Total liabilities end of the period (thousand NTD):5,702,357 13.Equity attributable to owners of parent end of the period (thousand NTD):1,879,649 14.Any other matters that need to be specified: None
2022/05/18	Clarification of Media Reports	1.Date of occurrence of the event:2022/05/17 2.Company name:Great Tree Pharmacy Co., Ltd. 3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office 4.Reciprocal shareholding ratios:N/A 5.Name of the reporting media:Economic Daily News 6.Content of the report: Economic Daily news headlines 「 Great Tree Pharmacy is expected to sell 400,000 saliva rapid screening kits , and it is estimated that it will contribute NTD70million in revenue. 」 「 Great Tree Pharmacy(6469)announced the sale of Gmate COVID-19 Ag Saliva kits,...,if all 400,000 kits are sold out

Date of announcement	Subject	Statement
		<p>and will be expected to contribute NTD 70million in revenue, which will help Great Tree's revenue continue to write a new record high and the monthly revenue has the opportunity to reach NTD1.5 billion. 」</p> <p>7.Cause of occurrence: To clarify media coverage on MOPS website.</p> <p>8.Countermeasures: The Company didn't provide financial forecast. The reported numbers are all self-estimated by Economic Daily News based on the company's released monthly revenue. The actual financial results shall be referred to the Company's official announcements.</p> <p>9.Any other matters that need to be specified: None</p>
2022/05/31	Announcement the Important resolutions of the 2022 Shareholders' Meeting	<p>1.Date of the shareholders' meeting:2022/05/31</p> <p>2.Important resolutions I.Profit distribution/deficit compensation: Agreed to endorsed fiscal 2021 profit distribution</p> <p>3.Important resolutions II.Amendments of the company charter: None.</p> <p>4.Important resolutions III.Business report and financial statements: Agreed to endorsed fiscal 2021 business report and financial statements</p> <p>5.Important resolutions IV.Election for directors and supervisors: None.</p> <p>6.Important resolutions V.Other matters: A.To approve new share issue through capitalization of earnings. B.Passed the amendments to the Company's Regulations Governing the Acquisition and Disposal of Assets. C.Passed the proposed private placement of common shares and/or private placement of domestic convertible corporate bonds.</p> <p>7.Any other matters that need to be specified: None.</p>
2022/05/31	Announcement of the resolution to distribute dividends, on behalf of major	<p>1.Date of the board of directors resolution:2022/05/31</p> <p>2.Type and monetary amount of dividend distribution: Cash Dividends NT\$3,700,000</p> <p>3.Any other matters that need to be specified: None.</p>

Date of announcement	Subject	Statement
	subsidiary Bai Lin Logistics Co., Ltd.	
2022/05/31	Announcement of the resolution to distribute dividends, on behalf of major subsidiary Chang Chun Teng Biotech Corp.Ltd.	<p>1.Date of the board of directors resolution:2022/05/31</p> <p>2.Type and monetary amount of dividend distribution: Cash Dividends NT\$59,354,000</p> <p>3.Any other matters that need to be specified: None.</p>
2022/06/01	Clarification of Media Reports	<p>1.Date of occurrence of the event:2022/05/31</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Name of the reporting media:investor</p> <p>6.Content of the report:</p> <p>The media news headlines 「 Great Tree Pharmacy's 2022 Annual Shareholders' Meeting passed a dividend of NTD 5.14 per share. In the second quarter, due to the increase in sales of anti-epidemic medical materials and drugs, operating revenue will reach a new high. 」</p> <p>「 It is estimated that the revenue in the second quarter will challenge NTD 3.6 billion, with a quarterly increase of 12.5%. The gross profit margin is expected to remain at the level of the first quarter. The after-tax net profit will increase by 40% to NTD 170 million, and the EPS will challenge a new high of NTD2.3. 」</p> <p>7.Cause of occurrence:To clarify media coverage on MOPS website.</p> <p>8.Countermeasures:</p> <p>The Company didn't provide financial forecast. The reported numbers are all self-estimated by investor news based on the company's released monthly revenue. The actual financial results shall be referred to the Company's official announcements.</p>

Date of announcement	Subject	Statement
		9.Any other matters that need to be specified: None
2022/06/07	The Company is invited to the online institutional investor conference held by CTBC Securities Co., Ltd. to present the Company's operational overview.	<p>1.Date of institutional investor conference:2022/06/10</p> <p>2.Time of institutional investor conference:15:50(Taiwan Time)</p> <p>3.Location of institutional investor conference:Online conference</p> <p>4.Outline of institutional investor conference: The Company is invited to the online institutional investor conference held by CTBC Securities Co., Ltd. to present operational and financial status.</p> <p>5.Any other matters that need to be specified: Presentation materials will be published on MOPS website on 06/10 after the conference is held.</p>
2022/06/13	Announcement on the ex-dividend base date and distribution date set by the chairman of the company	<p>1.Date of the resolution by the board of directors or shareholders' meeting, or of the decision by the company:2022/06/13</p> <p>2.Type (ex-rights or ex-dividend) (please write "Ex-rights", "Ex-dividend", or "Ex-rights and dividend"):Ex-dividend</p> <p>3.Type and monetary amount of dividend distribution: Cash dividends to common shareholders NT\$182,241,423</p> <p>4.Ex-rights (Ex-dividend) date:2022/06/29</p> <p>5.Last date before book closure:2022/06/30</p> <p>6.Book closure starting date:2022/07/01</p> <p>7.Book closure ending date:2022/07/05</p> <p>8.Ex-rights (Ex-dividend) record date:2022/07/05</p> <p>9.Deadline for applying the conversion of the debt voucher:Not applicable</p> <p>10.The closure period for the conversion of the debt voucher will start from the date:Not applicable</p> <p>11.The closure period for the conversion of the debt voucher will end on the date:Not applicable</p> <p>12.Payment date of cash dividend distribution:2022/07/21</p> <p>13.Any other matters that need to be specified: For the current cash dividend distribution, the dividend will be calculated to the amount of one whole NTD,and any</p>

Date of announcement	Subject	Statement
		decimal point below one NTD will be rounded down. Shares below one NTD will be adjusted from the largest decimal place, until the total amount of cash dividend has been distributed.
2022/06/22	The Company's Board of Directors approved the participation in a real estate tender.	<p>1.Date of the resolution by the board of directors or shareholders' meeting:2022/06/22</p> <p>2.Content of the investment plan: The Company's Board of Directors approved the participation in government agency's land tender and authorized the chairperson to handle related matters.</p> <p>3.Projected monetary amount of the investment:Not to exceed NT1,000,000,000.</p> <p>4.Projected date of investment:Depending on the bidding result.</p> <p>5.Source of capital funds:Own funds and bank loans.</p> <p>6.Specific purpose: In order to meet the needs of future long-term business development to increase operational performance.</p> <p>7.Any other matters that need to be specified: Relevant terms and conditions will be disclosed after the tender is awarded.</p>
2022/06/22	Announcement of the Board of Directors to authorize the Charirman to set the record date and matters related to the capitalization of earnings.	<p>1.Date of occurrence of the event:2022/06/22</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios: N/A</p> <p>5.Cause of occurrence: The Charirman was authorized by Board of Directors to set the record date of 2021 dividend distribution and matters related to the capitalization of earnings after the approval from government for the capital increase application.</p> <p>6.Countermeasures:N/A</p> <p>7.Any other matters that need to be specified: None.</p>
2022/06/22	Announcement of major resoultions of the Board of	<p>1.Date of occurrence of the event:2022/06/22</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p>

Date of announcement	Subject	Statement
	Directors.	3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office 4.Reciprocal shareholding ratios: N/A 5.Cause of occurrence: (1)Approval of applying for additonal credit line with China Trust Commercial Bank. (2)Approval of matters related to the capitalization of earnings. (3)Approval of the Board of Directors to authorize the Chairman to participate in government agency's land tender to handle related matters. 6.Countermeasures:N/A 7.Any other matters that need to be specified: None.
2022/07/08	To announce the Chairman sets the ex-rights and capital increase record date.	1.Date of the resolution by the board of directors or shareholders' meeting, or of the decision by the company:2022/07/07 2.Type (ex-rights or ex-dividend) (please write "Ex-rights", "Ex-dividend", or "Ex-rights and dividend"):Ex-rights 3.Type and monetary amount of dividend distribution: Stock dividends to common shareholders NT\$182,241,420 4.Ex-rights (Ex-dividend) date:2022/08/02 5.Last date before book closure:2022/08/03 6.Book closure starting date:2022/08/04 7.Book closure ending date:2022/08/08 8.Ex-rights (Ex-dividend) record date:2022/08/08 9.Deadline for applying the conversion of the debt voucher:NA 10.The closure period for the conversion of the debt voucher will start from the date:NA 11.The closure period for the conversion of the debt voucher will end on the date:NA 12.Payment date of cash dividend distribution:NA 13.Any other matters that need to be specified: (1)Shareholders can compose a complete share from stock dividends less than one share within 5 days from book

Date of announcement	Subject	Statement
		<p>closure strating date and these combined shares shall be allocated to one of the shareholders. The stock dividends less than one share after composition or forfeited composition by shareholders will be distributed in cash(removing the fractional part) and the shares will be subscribed by a specific person assigned by the Chairman of the Company who has been authorized by the Board of Directors.</p> <p>(2)The capitalization of retained earnings has been approved by Financial Supervisory Commission on 2022/06/17.</p> <p>(3)If there are any outstanding shares changed due to the change of the Company's capital sotck, the Boards of Directors meeting empowers the Chairman to handle.</p>
2022/07/08	The Company's Board of Director's resolution on issuing 2nd domestic unsecured convertible corporate bonds	<ol style="list-style-type: none"> 1.Date of the board of directors resolution:2022/07/07 2.Name [issue no.__ of (secured, unsecured) corporate bonds of _____ (company)]: Great Tree Pharmacy 2nd domestic unsecured convertible corporate bonds 3.Whether to adopt shelf registration(Yes/No):No 4.Total amount issued:Up to NT\$ 1 billion 5.Face value per bond:NTD 100 thousand 6.Issue price:Through auction , and the price shall not be lower than the face value. 7.Issuance period:3 year 8.Coupon rate:0% 9.Types, names, monetary values and stipulations of collaterals:NA 10.Use of the funds raised by the offering and utilization plan: Replenishing operating capital and to repay the bank loan. 11.Underwriting method:Through auction 12.Trustees of the corporate bonds:Undecided 13.Underwriter or agent:President Securities Corporation 14.Guarantor(s) for the issuance:NA 15.Agent for payment of the principal and interest: Department of Agency Services,Taishin Composite Securites Co.,

Date of announcement	Subject	Statement
		<p>Ltd.</p> <p>16.Certifying institution:Paperless share</p> <p>17.Where convertible into shares, the price and the rules for conversion: Related conversion rule are in accordance with the local regulation, conversion detail will be published after approved by the local authority.</p> <p>18.Sell-back conditions: Related conversion rule are in accordance with the local regulation, conversion detail will be published after approved by the local authority.</p> <p>19.Buyback conditions: Related conversion rule are in accordance with the local regulation, conversion detail will be published after approved by the local authority.</p> <p>20.Reference date for any additional share exchange, stock swap, or subscription: Related conversion rule are in accordance with the local regulation, conversion detail will be published after approved by the local authority.</p> <p>21.Possible dilution of equity in case of any additional share exchange, stock swap, or subscription: Related conversion rule are in accordance with the local regulation, conversion detail will be published after approved by the local authority.</p> <p>22.Any other matters that need to be specified: (1)After the corporate bonds is approved by the local authority, the board will authorize the chairman to decide the conversion price and related matter. (2)The important item for the corporate bonds, including issue price, conversion price,planned item, price allocation and other matter, are revised due to the change in regulation or outside environment, the board will authorize the chairman for decision.</p>
2022/07/28	Announcement that the	1.Date of occurrence of the event:2022/07/28

Date of announcement	Subject	Statement
	Company won the bid for 「 Taoyuan Aerotropolis Project Priority Industrial Zone Land Tender -B Base 」	<p>2.Company name:Great Tree Pharmacy CO., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Cause of occurrence: The Company and the co-bidders won the bid for 「 Taoyuan Aerotropolis Project Priority Industrial Zone Land Tender-B Base 」with a total price of NTD 1,679,968,400. The proportion of the area obtained by the Company and the co-bidders will not be known until the Taoyuan City Government has identified the realm. However, the total land price obtained in this case according to the quota authorized by the board of directors of the company on June 22,2022 shall not exceed NTD 1 billion. This case has not yet signed a contract with the Taoyuan City Government, and will be announced later when the relevant work is completed.</p> <p>6.Countermeasures:None.</p> <p>7.Any other matters that need to be specified: None.</p>
2022/08/11	Announcement the institution designated to collect and deposit for 2nd domestic unsecured convertible corporate bonds	<p>1.Date of occurrence of the event:2022/08/11</p> <p>2.Company name:Great Tree Pharmacy CO., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Cause of occurrence: Conducted in accordance with Subparagraph 2, Paragraph 1, Article 9 of the Regulations Governing the Offering and Issuance of Securities by Securities Issuers.</p> <p>6.Countermeasures:None.</p> <p>7.Any other matters that need to be specified: (1)Date of the agreement with the banks to collect and deposit the proceeds : 2022/08/11 (2)Name of the institution designated to collect the proceeds : First Commercial Bank ,Xinyi Branch (3)Name of the bank designated to deposit the proceeds : CTBC Bank ,Tunnan Branch</p>

Date of announcement	Subject	Statement
2022/08/11	Announcement on the 2022Q2 Consolidated financial report made by Board of Directors	<p>1.Date of the board of directors submitted or approved:2022/08/11</p> <p>2.Date of the audit committee approved:2022/08/11</p> <p>3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX): 2022/01/01~2022/06/30</p> <p>4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):7,159,008</p> <p>5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):1,937,608</p> <p>6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):439,383</p> <p>7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):456,927</p> <p>8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):362,579</p> <p>9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):362,395</p> <p>10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):4.07</p> <p>11.Total assets end of the period (thousand NTD):8,821,530</p> <p>12.Total liabilities end of the period (thousand NTD):6,675,433</p> <p>13.Equity attributable to owners of parent end of the period (thousand NTD):2,125,287</p> <p>14.Any other matters that need to be specified: None.</p>
2022/08/22	Announced the pricing for the 2nd domestic unsecured convertible corporate bonds of the Company	<p>1.Date of occurrence of the event:2022/08/22</p> <p>2.Company name:Great Tree Pharmacy CO., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Cause of occurrence: Conducted in accordance with the Procedures for Issuance and Conversion of the 2nd domestic unsecured convertible corporate bonds of Great Tree Pharmacy CO., Ltd.</p> <p>6.Countermeasures:None.</p>

Date of announcement	Subject	Statement
		<p>7.Any other matters that need to be specified: (1)The issuance of the 2nd domestic unsecured convertible corporate bonds of the Company was filed and effective through the Financial Supervisory Commission authorization No.1110350289 dated on Aug. 4,2022 (2)The record date of conversion price is on Aug. 22, 2022. The conversion price is set at NT\$304.98 per share with a conversion premium rate at 102%.</p>
2022/09/06	Announcement of the price determination and the relevant matters regarding privately placed first domestic unsecured convertible bonds	<p>1.Date of the board of directors resolution:2022/09/06 2.Name of the corporate bonds:Great tree Pharmacy Co., Ltd. privately placed first domestic unsecured convertible bonds 3.Total amount issued:NT\$220 million 4.Face value per bond:NT\$100,000 5.Issue price:Issued at face amount 6.Issuance period:Three years 7.Coupon rate:Coupon rate 0% 8.Types, names, monetary values and stipulations of collaterals:None 9.Use of the funds raised by the offering and utilization plan: The funds raised hereby shall serve to either increase working capital, strengthen the financial structure and support the company to expand its marketing channels increase its market share. 10.Trustees of the corporate bonds:N/A 11.Guarantor(s) for the issuance:N/A 12.Agent for payment of the principal and interest: The Company's shareholder services agent 13.Where convertible into shares, the price and the rules for conversion: The pricing date has been set on 2022/09/06, and the conversion price on the price date has been set at NTD270.5 per share. For details, please refer to the issuing terms. 14.Sell-back conditions:None</p>

Date of announcement	Subject	Statement
		<p>15. Buyback conditions:</p> <p>(1) At any time on or after the following day of third month of the Issue Date and until 40 days prior to the Maturity Date, if the Closing Price of the Shares is at least 30 percent above conversion price in any period of 30 consecutive Trading Days, The Company may, having given 30 days' notice to the Bondholders with registered mail, redeem the Bonds in whole at face amount within 5 business days of Redemption Record Date. (The aforementioned period begins at date of sending and expires at the Record Date of Redemption. The aforementioned period does not fall within the period during which bond conversion is suspended in accordance with Condition 9 in the terms of issuance and conversion)</p> <p>(2) At any time on or after the following day of third month of the Issue Date and until 40 days prior to the Maturity Date, if the outstanding bonds is less than the 10% of the total bonds issued, The Company may, having given 30 days' notice to the Bondholders with registered mail, redeem the Bonds in whole at face amount within 5 business days of Redemption Record Date. (The aforementioned period begins at date of sending and expires at the Record Date of Redemption. The aforementioned period does not fall within the period during which bond conversion is suspended in accordance with Condition 9 in the terms of issuance and conversion)</p> <p>(3) If the Bondholders have not replied to the Company's shareholder services agent in writing before the Record Date of Redemption listed in the Redemption Notice, The Company shall redeem all the outstanding Bonds in cash at the amount equal to the face amount of the bonds within 5 business days after the Record Date of Redemption. (The Notice shall be effective upon arrival based on the date of postmark).</p> <p>16. Reference date for any additional share exchange, stock swap, or subscription: Subject to and upon compliance with the provisions of the Terms and provisions of Article 10, 11, 13, and 14, upon the request to The Company's shareholder services agent, the conversion right attaching to the Bond may be exercised, at the option of the Bondholder, at any time on or after the 91st calendar day after the Issue Date until the Maturity Date, with exception for (1) the lock-up period for common shares in accordance with the law (2) the period beginning on the 15 business days before the book closure date for the issuance of bonus shares, the distribution of</p>

Date of announcement	Subject	Statement
		<p>cash dividends, or the subscription of new shares resulting from a cash capital increase until the record date of distribution (3) the period beginning on the record of a capital reduction until one day prior to the trading day on which the shares of the Company are reissued and replaced after such capital reduction (4) the period beginning on the commencement date conversion(subscription) is suspended due to change of par value until one day prior to the trading day on which the shares of the Company are reissued and replaced.</p> <p>17.Possible dilution of equity in case of any additional share exchange, stock swap, or subscription: If the bonds have been converted to Shares at NT\$270.5 , possible dilution of equity is around 0.90%.</p> <p>18.For additional share exchange or subscription, possible influence of change in shareholding ratio of TPEX-listed common shares if all privately placed corporate bonds are converted and shares subscribed for (no.of TPEX -listed common shares (a), (a) / outstanding common shares):0.90%</p> <p>19.Please explain any countermeasures for lower circulation in shareholding if the aforesaid estimated no.of TPEX-listed common shares does not reach 5 million and the ratio does not reach 25%:N/A</p> <p>20.Any other matters that need to be specified: (1)For matters required to be done or not provided, the Chairman is authorized by the board of directors with full power to handle in accordance with laws and regulations. (2)For the agenda of the private placement of securities, in accordance with Article 43-6, Securities and Exchange Act, and the matters requiring supplementary explanation, please refer to private placement section, Investment Section, MOPS(http://mpos.twse.com.tw)</p>
2022/09/07	Announcement of the fully paid-in payments of the Company's 2nd domestic unsecured convertible corporate bonds	<p>1.Date of occurrence of the event:2022/09/07</p> <p>2.Company name:Great tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:NA</p> <p>5.Cause of occurrence: Based on Subparagraph 2, Paragraph 1, Article 9 of Regulations Governing the Offering and Issuance of Securities by</p>

Date of announcement	Subject	Statement
		<p>Securities Issuers, the Company conducts the domestic 2nd unsecured convertible corporate bonds and the Company collection bank has fully collected all the funds should be raised and remitted NTD1,042,087,730 to the authorized deposit bank.</p> <p>6.Countermeasures:None.</p> <p>7.Any other matters that need to be specified:None.</p>
2022/09/12	Update private placement area-It should be reported within two days from the date of the resolution of board of directors(private placement conversion)	<p>1.Date of occurrence of the event:2022/09/12</p> <p>2.Company name:Great Tree Pharmacy Co., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Cause of occurrence: The Company amended the information should be reported within two days of the Board of Directors' approval on April 6,2022.</p> <p>6.Information items/ statements to be corrected: The informations should be reported within two days of the Board of Directors' approval(private placement of corporate bonds)</p> <p>7.Amounts/ contents/ number of page to be corrected: " The counterparties for the private placement and their relationship with the Company":Before the proposal of the Company's shareholders' meetings, the Company has not found specific persons yet and is proposed to authorize the Board of Directors to find specific persons and handle related matters.</p> <p>8.Amounts/ contents/ number of page after correction: " The counterparties for the private placement and their relationship with the Company":</p> <p>(1)Before the proposal of the Company's shareholders' meetings, the Company has not found specific persons yet.</p> <p>(2)On Sep.6,2022,the board of directors has negotiated the counterparties, and the list is as follows: Sugi Holings Co., Ltd. has no relationship with the Company.</p> <p>(3)For the subscriber as a legal person in the abovementioned list, the names of its 10 largest shareholders, the</p>

Date of announcement	Subject	Statement
		<p>holding percentage of each, and their relationship with the subscriber are listed, please refer to the private placement area of MOPS.</p> <p>9.Countermeasures:Update private placement area-It should be reported within two days from the date of the resolution of board of directors(private placement conversion)</p> <p>10.Any other matters that need to be specified:None.</p>
2022/09/15	Announcement of the fully paid-in payment of the Company's privately placed first domestic unsecured convertible bonds	<p>1.Date of occurrence of the event:2022/09/15</p> <p>2.Company name:Great Tree Pharmacy CO., Ltd.</p> <p>3.Relationship to the Company (please enter "head office" or "subsidiaries"):Head office</p> <p>4.Reciprocal shareholding ratios:N/A</p> <p>5.Cause of occurrence: The payments of NT\$220 million in total of the Company's privately placed first domestic unsecured convertible bonds has been made in full. The Place is Sugi Holdings Co., Ltd.</p> <p>6.Countermeasures:None.</p> <p>7.Any other matters that need to be specified: For the matters regarding privately placed first domestic unsecured convertible bonds, please refer to investment section under private placement section on MOPS website.</p>
2022/11/10	The Board of Directors ratified the amendments to the "2022 1st employee stock warrants issuance and stock subscription methods"	<p>1.Date of occurrence of the event:2022/11/10</p> <p>2.Date of the original announcement and reporting:2022/02/25</p> <p>3.Summary of the content originally announced and reported: Great Tree Pharmacy Co., Ltd.'s Board of Directors resolved to issue 2022 1st employee stock warrants.</p> <p>4.Reason for change and its main content: (1)In order to meet the actual needs of the company and the requirements of the Financial Supervisory Commission,the amendments to the "2022 1st employee stock warrants issuance and stock subscription methods" (2)Content before modification:</p>

Date of announcement	Subject	Statement
		<p>II 、 Issue period: Within one year since the date of receipt for notice of the competent authority's approval and effectiveness;issued at once or in tranches depending on actual requirements.The actual issue date is determined by the chairman authorized by the board of directors.</p> <p>III 、 Eligibility criteria for optionees: (I)Restricted to the full-time employees with specific positions or special contributions of the company or its domestic and foreign subsidiaries that are with ove 50%(inclusive) shareholding held by the company directly or indirectly. (II)The Chairman shall determine the employees who are entitled to the options and the number of options to be granted after taking into consideration factors including but not limited to responsibilities ,work performance and overall contribution or development potential and other factors, and then submit the decision to the Board of Directors for approval.For employees who are directors or managerial officers,approval by the Remuneration Committee must be obtained first, which shall then be submitted to the Boards of Directors for approval. (III)The cumulative number of shares a single employee can subscribe for by excercising the options granted to him/her by the Company under Paragraph 1,Article 56-1 of the Securities Issuers (the” Regulations Governing Offering and Issuance”),in combination with the cumulative number of restricted stock awards obtained by such employee, shall not exceed 0.3% of the total issued shares. The above, in combination with the cumulative number of shares such employee can subscribe for by exercising the stock wasrrants granted under Paragraph 1, Article 56 shall not exceed 1% of the total issued shares.</p> <p>IV 、 Number of total issued of the employee stock warrants: The total number of employee stock warrants is 4,000 units, each unit of stock warrant can be subscribed for 1,000 shares, and the total of new ordinary shares to be issued by the Company due to the exercise of stock warrants is 4,000,000 shares.</p>

Date of announcement	Subject	Statement								
		<p>V、The criteria for subscription:</p> <p>(II)Period of subscription rights:</p> <p>1.Optionees may exercise their options, respectively ,after 2 years have elapsed since the granting of the stock warrants. The duration of these stock warrants shall be 5 years. The stock warrants may not be transferred ,pledged ,assigned as a gift, or otherwise disposed by the optionee, except by inheritance. Once duration has elapsed, rights for options that have not been exercised shall be deemed as waived, and optionees may no longer claim right to exercise their subscription rights.</p> <table data-bbox="815 580 1590 804"> <thead> <tr> <th>Grant period</th> <th>Ceiling for proportion of stock warrants exercisable(accumulated)</th> </tr> </thead> <tbody> <tr> <td>After 2 years</td> <td>40%</td> </tr> <tr> <td>After 3 years</td> <td>70%</td> </tr> <tr> <td>After 4 years</td> <td>100%</td> </tr> </tbody> </table> <p>VII、Adjustment of subscription price:</p> <p>(III)If cash dividend distributed exceeds 1.5% of the common stock market price after the issuance of the stock warrant, the exercise unit price will be adjusted according to the following formula: (computation up to decimal two digits of New Taiwan dollars and the fraction is rounded off at 4 to become 5)</p> <p>Adjusted subscription price= exercise price before adjustment X (1-percentage of cash dividend to the common stock market price).</p> <p>The common stock market price should be the simple average closing price of either one, three or five days prior to the announcement date of the ex-dividend book closure period.</p> <p>Modified content:</p>	Grant period	Ceiling for proportion of stock warrants exercisable(accumulated)	After 2 years	40%	After 3 years	70%	After 4 years	100%
Grant period	Ceiling for proportion of stock warrants exercisable(accumulated)									
After 2 years	40%									
After 3 years	70%									
After 4 years	100%									

Date of announcement	Subject	Statement
		<p>II 、 Issue period: Within two years since the date of receipt for notice of the competent authority's approval and effectiveness; issued at once or in tranches depending on actual requirements. The actual issue date is determined by the chairman authorized by the board of directors.</p> <p>III 、 Eligibility criteria for optionees: (I) Full-time or part-time employees of the Company and a domestic or foreign company which has the controlling or subordinate relationship with the Company as of the Grant Date in accordance with 2018.12.27 No.1070121068 promulgated by the FSC are eligible participants of the Plan. For the purpose of this Plan, full-time and part-time employees shall be as follows: a. Full-time employee means a person employed by the Company or a domestic or foreign company which has the controlling or subordinate relationship with the Company, who undertakes the assignment and gets paid regularly according to his/her employment contract. b. Part-time employee means a person employed by the Company or a domestic or foreign company which has the controlling or subordinate relationship with the Company on an hourly basis, short-term basis (works fewer than the standard working hours per day) or for a specific project and get paid on a monthly or project rate according to his/her fixed term employment contract. (II) The actual number of shares recognized by an employee will be determined by the Chairman after approval by the Chairman and with the consent of the Board of Directors, taking into account the individual work performance, overall contribution, special merit or other conditions for reference in management, etc., except that the identity of the director or manager on the list of recognized shareholders shall be approved by the Remuneration Committee; If the list of shareholders is not a manager, it is necessary to obtain the consent of the Audit Committee before submitting the board resolution. (III) The cumulative number of shares a single employee can subscribe for by exercising the options granted to him/her by the Company under Paragraph 1, Article 56-1 of the Securities Issuers (the "Regulations</p>

Date of announcement	Subject	Statement
		<p>Governing Offering and Issuance”), in combination with the cumulative number of restricted stock awards obtained by such employee, shall not exceed 0.3% of the total issued shares. The above, in combination with the cumulative number of shares such employee can subscribe for by exercising the stock warrants granted under Paragraph 1, Article 56 shall not exceed 1% of the total issued shares. However, at a special approval from industrial in-charging governmental authority, the total shares granted to a single employee under both the employee stock option plans and the RSA rule may be exempted from the above-mentioned limitation.</p> <p>IV、Number of total issued of the employee stock warrants: The total number of employee stock warrants is 4,500 units, each unit of stock warrant can be subscribed for 1,000 shares, and the total of new ordinary shares to be issued by the Company due to the exercise of stock warrants is 4,500,000 shares.</p> <p>V、The criteria for subscription: (II) Period of subscription rights: 1. Optionees may exercise their options, respectively, after 2 years have elapsed since the granting of the stock warrants. The duration of these stock warrants shall be 5 years. The stock warrants may not be transferred, pledged, assigned as a gift, or otherwise disposed by the optionee, except by inheritance. Any Option not exercised during the 5-year period shall become void upon expiration, and in such case, the Optionee shall be deemed to have waived his/her options and the optionee has no right to contest otherwise. From the date when two full years have elapsed after the Grant Date, the Optionee may exercise his/her options in accordance with the schedule and percentage respectively Schedule A: The number of options to be granted will be 2,500 units and from the date when two full years have elapsed after the Grant Date, the Optionee may exercise all of his/her options. Schedule B: The number of options to be granted will be 2,000 units and the exercisable schedule and percentage listed below:</p> <p>Grant period Ceiling for proportion of stock options exercisable</p>

Date of announcement	Subject	Statement
		<p style="text-align: center;">(accmulated)</p> <p style="text-align: center;">After 2 years 50%</p> <p style="text-align: center;">After 3 years 100%</p> <p>VII、Adjustment of subscription price:</p> <p>(III)After the ESO are granted, the exercise price of each ESO shall be subject to adjustment in accordance with the following formula (computation up to decimal two digits of New Taiwan dollars and the fracion is rounded off at 4 to becom 5) in the case of cash dividend distributed:</p> <p style="text-align: center;">Adjusted exercise price= Exercise price prior to adjustment X (1 - cash sividend per share / market price per share)</p> <p style="text-align: center;">The market price per share shall be the simple arithmetic average of the closing price of shares on the first, third or fifth business day immeidately prior to the date when the Company announces that the company's shareholders' register is closed as for cash dividends.</p> <p>(IV)If the cash dividends and stock dividends are issued at the same time(including capitalization of retained earnings and capitalization of capital surplus),the exercise price shall be adjusted in accordance with the cash dividends and then the stock sividends.</p> <p>5.Impact on the Company's finance and business after the change:None.</p> <p>6.Any other matters that need to be specified:None.</p>
2022/11/10	Announcement on the 2022Q3 Consolidated financial report made by Board of Directors	<p>1.Date of the board of directors submitted or approved:2022/11/10</p> <p>2.Date of the audit committee approved:2022/11/10</p> <p>3.Start and end dates of financial reports or unaudited financial information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):2022/01/01~2022/09/30</p> <p>4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):10,772,573</p> <p>5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):2,917,505</p>

Date of announcement	Subject	Statement
		<p>6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):647,441</p> <p>7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):670,893</p> <p>8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):532,065</p> <p>9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):531,733</p> <p>10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):5.97</p> <p>11.Total assets end of the period (thousand NTD):10,023,266</p> <p>12.Total liabilities end of the period (thousand NTD):7,609,128</p> <p>13.Equity attributable to owners of parent end of the period (thousand NTD):2,393,180</p> <p>14.Any other matters that need to be specified:None.</p>
2022/12/15	The Board of Directors ratified the amendments to the "2022 1st employee stock warrants issuance and stock subscription methods"	<p>1.Date of occurrence of the event:2022/12/15</p> <p>2.Date of the original announcement and reporting:2022/11/10</p> <p>3.Summary of the content originally announced and reported: The Board of Directors ratified the amendments to the ” 2022 1st employee stock warrants issuance and stock subscription methods”</p> <p>4.Reason for change and its main content: (1)To meet the requirements of the Financial Supervisory Commission,the amendments to the ”2022 1st employee stock warrants issuance and stock subscription methods”</p> <p>(2)Content before modification: III 、Eligibility criteria for optionees: (II)The actual number of shares recognized by an employee will be etermined by the Chairman after approval by the Chairman and with the consent of the Board of Directors, taking into account the individual work performance, overall contribution, special merit or other conditions for reference in management,etc.,</p>

Date of announcement	Subject	Statement
		<p>except that the identity of the director or manager on the list of recognized shareholders shall be approved by the Remuneration Committee; If the list of shareholders is not a manager, it is necessary to obtain the consent of the Audit Committee before submitting the board resolution.</p> <p>IV、Number of total issued of the employee stock warrants: The total number of employee stock warrants is 4,500 units, each unit of stock warrant can be subscribed for 1,000 shares, and the total of new ordinary shares to be issued by the Company due to the exercise of stock warrants is 4,500,000 shares.</p> <p>VII、Adjustment of subscription price: (II)After the warrants have been granted, in case of any change in the number of the common shares of the Company (i.e, allotment of new shares, capitalization of earnings, capitalization of capital surplus, merger with or acquisition of another company ,split of stocks, participating in the offering of global depositary receipt by way of rights issue), the subscription price shall be adjusted based on the following formula(to be rounded up to the nearest NT\$0.1).</p> <p style="text-align: center;">Adjusted subscription price= Subscription price before adjustment X [Number of issued share+ (Per share subscription price x Number of new shares)/per share market price] / (Number of issued shares+Number of new shares)</p> <p>(V)After the warrants have been granted, if not for capital deduction due to cancellation of treasury stock, the shares of common stock reduces, the subscription price shall be adjusted based on the following formula(to be rounded up to the nearest NT\$0.1).</p> <p>When capital reduction plan offsetting company losses:</p>

Date of announcement	Subject	Statement
		<p>Adjusted subscription price = Subscription price before adjustment X (shares issued before capital reduction/shares issued after capital reduction)</p> <p>When reducing capital: Adjusted subscription price = (subscription price before adjustment — the amount of cash returned per share) X (number of issued and outstanding shares before capital reduction /number of issued and outstanding shares after capital reduction)</p> <p>Modified content:</p> <p>III 、 Eligibility criteria for optionees: (II)The actual number of shares recognized by an employee will be determined by the Chairman after approval by the Chairman and with the consent of the Board of Directors, proposed assignment criteria that take into account the individual work performance ,overall contribution,special merit or other conditions for reference in managerment,etc., except that the identity of the director or manager on the list of recognized shareholders shall be approved by the Remuneration Committee; If the list of shareholders is not a manager, it is necessary to obtain the consent of the Audit Committee before submitting the board resoulution.</p> <p>IV 、 Number of total issued of the employee stock warrants: The employee sotck warrants are dividend into two categories,A and B (category A:all employees, category B:supervisors and special meritorious persons),2500 units are issued for category A, and 2,000 units for category</p>

Date of announcement	Subject	Statement
		<p>B. The total number of employee stock warrants is 4,500 units, each unit of stock warrant can be subscribed for 1,000 shares, and the total of new ordinary shares to be issued by the Company due to the exercise of stock warrants is 4,500,000 shares.</p> <p>VII - Adjustment of subscription price:</p> <p>(II) After the warrants have been granted, in case of any change in the number of the common shares of the Company (i.e., allotment of new shares, capitalization of earnings, capitalization of capital surplus, merger with or acquisition of another company, split of stocks, participating in the offering of global depository receipt by way of rights issue), the subscription price shall be adjusted based on the following formula (to be rounded up to the nearest NT\$0.1). If there is an increase in the number of issued ordinary shares due to change of the par value of shares, the adjustment shall be made on the base date of the new share exchange, but the actual payment shall be adjusted on the date of full payment of the shares.</p> <p>Adjusted subscription price = Subscription price before adjustment X [Number of issued share + (Per share subscription price x Number of new shares) / per share market price] / (Number of issued shares + Number of new shares)</p> <p>Change of the par value of shares: Adjusted subscription price = Subscription price before adjustment X (total number of outstanding shares before change of the par value of shares / total number of outstanding shares after change of the par value of shares)</p>

Date of announcement	Subject	Statement
		<p>(V)After the warrants have been granted, if not for capital deduction due to cancellation of treasury stock, the shares of common stock reduces, the subscription price shall be adjusted based on the following formula(to be rounded up to the nearest NT\$0.1) If there is a decrease in the number of ordinary shares due to change of the par value of shares, the amount adjusted on the base date of the new share swap will be adjusted accordingly.</p> <p>When capital reduction plan offsetting company losses: Adjusted subscription price= Subscription price before adjustment X (shares issued before capital reduction/shares issued after capital reduction)</p> <p>When reducing capital: Adjusted subscription price= (subscription price before adjustment – the amount of cash returned per share) X (number of issued and outstanding shares before capital reduction / number of issued and outstanding shares after capital reduction)</p> <p>Change of the par value of shares: Adjusted subscription price= Subscription price before adjustment X (total number of outstanding shares before change of the par value of shares / total number of outstanding shares after change of the par</p>

Date of announcement	Subject	Statement
		<p>value of shares)</p> <p>5.Impact on the Company's finance and business after the change: None.</p> <p>6.Any other matters that need to be specified: None.</p>